Embecta Corp (EMBC)vsWest Pharmaceutical Services Inc (WST)
EMBC
Embecta Corp
$3.49
+6.08%
HEALTHCARE · Cap: $184.51M
WST
West Pharmaceutical Services Inc
$314.50
-0.89%
HEALTHCARE · Cap: $23.23B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 209% more annual revenue ($3.22B vs $1.04B). WST leads profitability with a 16.9% profit margin vs 10.7%. EMBC trades at a lower P/E of 1.6x. WST earns a higher WallStSmart Score of 65/100 (C+).
EMBC
Buy53
out of 100
Grade: C-
WST
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.4%
Fair Value
$7.32
Current Price
$3.49
$3.83 premium
Margin of Safety
-55.4%
Fair Value
$158.40
Current Price
$314.50
$156.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 14.4%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : WST
The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.
Key Dynamics to Monitor
EMBC profiles as a declining stock while WST is a growth play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
WST is growing revenue faster at 21.0% — sustainability is the question.
WST generates stronger free cash flow (47M), providing more financial flexibility.
Bottom Line
WST scores higher overall (65/100 vs 53/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a prominent medical technology company dedicated to innovating insulin delivery systems for diabetes management. Established as a spin-off from Becton, Dickinson and Company, Embecta offers a wide range of advanced products, including state-of-the-art insulin pens and syringes, designed to improve patient outcomes. With a strong commitment to operational excellence and customer satisfaction, Embecta is strategically poised to leverage growth opportunities in the expanding diabetes care market, thereby reinforcing its leadership role in this critical sector.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?